How effective is Kladribine for multiple sclerosis?

Cladribine was originally developed as chemotherapy to combat leukemia. The ability of this drug to inhibit lymphocyte growth, which is assumed that it is part of the disease process of multiple sclerosis, which makes it possible to treat multiple sclerosis. Since October 2011, this drug has not been approved for the treatment of multiple sclerosis in the US, because US federal drugs (FDA) felt that other tests were needed.

The examination of Kladribine for multiple sclerosis has indicated that this drug may have some value as a treatment of relapsed types of multiple sclerosis due to the effect on lymphocytes, white blood cells fighting diseases. Multiple sclerosis is an autoimmune disease and scientists theorize that lymphocytes are crucial in the formation of brain lesions that characterize this disease. A 2009 research study tested two different levels of Kladribine dosing on multiple sclerosis. Study participants with a lower dose had 58% lower the episodes of multiple sclerosis, while those at VThe more than one dose had a 55% lower recurrence rate. According to this research, there was also a decrease in brain lesions due to the use of this drug.

However, the possible side effects of clabridine may be serious. Lymphopenia or low blood lymphocyte levels is the expected side effect of this drug. Lymphocytes are important for the body's immune system and the insufficient level of this white blood cell can lead to greater susceptibility to infection. The increased risk of cancer was reportedly another possible side effect of the drug.

In addition to causing lymphopenia, according to some patients, it may also induce headaches and nasal passages. Other side effects include nausea, diarrhea and loss of appetite. When this medicine is used to treat leukemia, peripheral neuropathy- there may also be a condition in which the nerves in the arms and legs may be dull and sensitive to hot and cool and mdashl. Using analgesics as a napRoxen, ibuprofen and aspirin are not recommended in combination with Kladribine because it can hide signs of fever that could indicate infection.

Since June 22, 2011, Kladribine testing was suspended for multiple sclerosis. According to the FDA, the drug company did not fully meet the FDA standards. Although the use of Kladribin for multiple sclerosis has not been generally approved in Europe since October 2011, it has been approved in Russia and Australia.